MCT1是多发性骨髓瘤来那度胺维持治疗的预测标志物
研究评估654例接受来那度胺、沙利度胺或硼替佐米维持治疗的多发性骨髓瘤患者的MCT1与CD147表达,发现MCT1高表达者来那度胺维持治疗的无进展生存和总生存显著缩短,而硼替佐米维持治疗中MCT1表达无显著影响,并在沙利度胺队列中验证了MCT1对免疫调节药物维持治疗的预测作用。
要点
- MCT1高表达者来那度胺维持治疗的无进展生存为31.9个月,低于MCT1低表达者的48.2个月(P = .03)。
- MCT1高表达者来那度胺维持治疗的总生存为75.9个月,MCT1低表达者未达到(P = .001)。
- 沙利度胺维持治疗中MCT1高表达者总生存为83.6个月,MCT1低表达者未达到(P = .03)。
核心结论
- MCT1表达被确立为多发性骨髓瘤患者来那度胺维持治疗反应的预测标志物。
研究设计与样本
- 研究纳入654例多发性骨髓瘤患者,其中接受来那度胺维持治疗455例、沙利度胺维持治疗98例、硼替佐米维持治疗101例,采用基因表达谱和RNA测序评估MCT1与CD147表达,并与无进展生存和总生存数据关联。
- 在独立沙利度胺维持治疗队列中验证MCT1对免疫调节药物维持治疗的预测作用,并行功能验证。
主要发现
- 来那度胺维持治疗中,MCT1高表达者的无进展生存为31.9个月,MCT1低表达者为48.2个月(P = .03);总生存MCT1高表达者为75.9个月,MCT1低表达者未达到(P = .001)。
- 硼替佐米维持治疗中,MCT1表达对无进展生存或总生存均无显著影响。
- 沙利度胺维持治疗验证队列中,MCT1高表达者总生存为83.6个月,MCT1低表达者未达到(P = .03)。
- 人骨髓瘤细胞系中MCT1过表达显著降低来那度胺疗效,而硼替佐米治疗在体外或骨髓瘤异种移植模型中均未观察到变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who received lenalidomide (n = 455), thalidomide (n = 98), or bortezomib (n = 101) maintenance were assessed by gene expression profiling and RNA sequencing, followed by correlation of MCT1 and CD147 expression with data for progression-free survival (PFS) and overall survival (OS). Patients with high expression levels of MCT1 showed significantly reduced PFS (31.9 months vs 48.2 months in MCT1high vs MCT1low; P = .03) and OS (75.9 months vs not reached [NR] in MCT1high vs MCT1low; P = .001) in cases with lenalidomide maintenance, whereas MCT1 expression had no significant impact on PFS or OS in cases with bortezomib maintenance. We validated the predictive role of MCT1 for IMiD-based maintenance in an independent cohort of patients who received thalidomide (OS, 83.6 months vs NR in MCT1high vs MCT1low; P = .03). Functional validation showed that MCT1 overexpression in human MM cell lines significantly reduced the efficacy of lenalidomide, whereas no change was observed with bortezomib treatment, either in vitro or in a MM xenograft model. Our findings have established MCT1 expression as a predictive marker for response to lenalidomide-based maintenance in patients with MM.
引用
- Stroh J, Seckinger A, Heider M, et al. MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Adv. 2022. PMID: 34768284. doi:10.1182/bloodadvances.2021005532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。